Remember
 
+
 
+
 Do You Know the Most Important and Timely Stock Plays During the Trading Week? View Our Power Rankings.
 
russurban Followed KIQ1 day ago
russurban Placed a 'Buy' Sentiment on VXRTMore than a week ago
russurban Placed a 'Buy' Sentiment on OTLKMore than a week ago
anonusers Placed a 'Sell' Sentiment on UNVC5 days ago
anonusers Placed a 'Buy' Sentiment on HOMEMore than a week ago
anonusers Placed a 'Sell' Sentiment on WBAMore than a week ago
stockarticles Placed a 'Buy' Sentiment on BBMore than a week ago
stockarticles Followed BBMore than a week ago
stockarticles Placed a 'Buy' Sentiment on SNAPMore than a week ago
 
Most Discussed Stocks through Posts and Reactions on SpeculatingStocks  VXRT  •  OTLK  •  PINS  •  BB  •  TWTR  •  CGC  •  ARCI  •  LULU  •  SNAP  •  IRBT
     
 

Wednesday, July 18, 2018

SpeculatingStocks.com Stock Pick



Stock Price: $6.75

Mesoblast Ltd. engages in the research, development, and market of pharmaceutical products. Its medicines target the cardiovascular conditions, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.

MESO is a company that has flashed on the radar through a recent financing deal for $50 million on July 1st and through a big move of 12.5% in its shares on July 17th, 2018. MESO also expects another $40 million cash in its doors after announcing that they entered strategic alliance with Tasly Pharmaceutical Group, and that Mesoblast will receive $40M on closing. This is on top of cash of $59.5 million that already sits on their balance sheet as of March 31, 2018.


MESO could be sitting with cash of approximately $149 million, while it is trading at a market cap of only $572 million. This possible cash reserve amount would give the company plenty of funding to pursue their commitment to bring to market their disruptive cellular medicines to treat serious and life-threatening illnesses.

Mesoblast just entered into a strategic alliance with Tasly Pharmaceutical Group, for the development, manufacture and commercialization in China of Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product candidates MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It could end up being an extremely sweet deal for MESO.

It wouldn't be surprising at all to see MESO trade above a market cap of $1 billion in the near future once the market realizes what this company has going on.

Speculative Score: 3

1 Being the Least Speculative and Most Confident

10 Being the Most Speculative and Possibly the Most Risky

 
     
Untitled Document